This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Cancer
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
-
Alabama Oncology, Birmingham, Alabama, United States, 35233
Eastern CT and Hematology and Oncology Associates, Norwich, Connecticut, United States, 06360
Southern Illinois Healthcare, Carterville, Illinois, United States, 62918
Hope and Healing Cancer Services, Hinsdale, Illinois, United States, 60521
Cancer Care Specialists of Illinois, O'Fallon, Illinois, United States, 62269
Illinois Cancer Care, Peoria, Illinois, United States, 61615
Northwest Oncology and Hematology, Rolling Meadows, Illinois, United States, 60008
Fort Wayne, Fort Wayne, Indiana, United States, 46804
St. Claire Healthcare, Morehead, Kentucky, United States, 40351
Lake Regional Health, Osage Beach, Missouri, United States, 65065
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 99 Years
ALL
No
Tempus AI,
Michelle Ting-Lin, MD, STUDY_DIRECTOR, Tempus AI, Inc.
2029-06-01